Pharmacokinetics of high-titer anti–SARS-CoV-2 human convalescent plasma in high-risk children
고위험 소아에서 고역가 항-SARS-CoV-2 인간 회복기 혈장의 약동학
Clinical Trial
[키워드] age
Analysis
Anti-spike
anti-Spike IgG
antibody
antibody kinetics
antibody production
Antibody titer
Antibody titers
appear
characterized
children
convalescent plasma
coronavirus
COVID-19
declined
develop
disease
Donor
ELISA assays
enrolled
epitope
Euroimmun
evaluated
expected
exposure to
funding
IgG
immunoglobulins
Infectious disease
Kinetics
Kinetics of antibodies
median age
Mild
Mild disease
neutralization capacity
neutralization titer
neutralizing capacity
NIH
passive transfer
performed
pharmacokinetic
pharmacokinetics
plasma
PROTECT
receive
recipient
Research
Safe
SARS-CoV-2
Serious Adverse Event
Serious Adverse Events
severe disease
Spike protein
symptom onset
transferred
transfused
transfusion
Trial registration
underlying condition
underlying conditions
unlikely
virus neutralization assays
weight
while
[DOI] 10.1172/jci.insight.151518 PMC 바로가기 [Article Type] Clinical Trial
[DOI] 10.1172/jci.insight.151518 PMC 바로가기 [Article Type] Clinical Trial